Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Status:
Completed
Trial end date:
2019-07-31
Target enrollment:
Participant gender:
Summary
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral
small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24
weeks in subjects with mild Alzheimer's disease. The primary objective is to demonstrate
significant improvement relative to placebo-treatment in episodic memory function, as
assessed by the Hopkins Verbal Learning Test. Secondary endpoints include Clinical Dementia
Rating scale (CDR), Wechsler Memory Scale (WMS), Mini-Mental-Status-Examination (MMSE) and
Cerebrospinal fluid (CSF) biomarkers of AD disease activity and progression.
Phase:
Phase 2
Details
Lead Sponsor:
EIP Pharma Inc EIP Pharma, LLC
Collaborators:
VU University Medical Center Worldwide Clinical Trials